MedTrace Logo

Combination of Olmesartan Effect on Myocardial Viability of Patients With Dilated Cardiomyopathy

NCT04174456 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-08-26

No results posted yet for this study

Summary

The study proceeds with prospective, randomized, open and controlled clinical trials. The subject of the investigator's study was the first patient diagnosed with dilated cardiomyopathy. Subjects who agreed to participate in the study and were determined to meet the selection / exclusion criteria were randomly assigned to each group, and the experimental group was treated with 20 mg of olmesartan and 5 mg of rosuvastatin for 6 months, and the control group is treated with 40 mg of valsartan and 5 mg of rosuvastatin.

Conditions

  • Dilated Cardiomyopathy

Interventions

DIAGNOSTIC_TEST

FDG PET

baseline and 6-month follow-up FDG PET

Sponsors & Collaborators

  • Dong-A University

    lead OTHER

Principal Investigators

  • Kyungil PARK · Dong-A University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-01
Primary Completion
2021-12-01
Completion
2021-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04174456 on ClinicalTrials.gov